C. R. Bard, Inc.

COLLEGE PARK, Md., Sept. 25, 2024 /PRNewswire/ -- Medcura, Inc., a leader in innovative hemostasis solutions that deploy patented biopolymer technologies to control surgical bleeding, is pleased to announce it has received a 2024/2025 Best Technology in Spine Award for LifeGel™ Absorbable Hemostatic Gel. Continue Reading 2024 Orthopedics This Week: Spine technology Awards Medcura will formally accept the award at the North American Spine Society (NASS) meeting in Chicago this week. Presented by Orthopedics This Week, the Best Technology in Spine Award recognizes "inventors, engineers and others who chase the dream of advancing spine surgery — and pay for that dream with marathon engineering sessions and more than a few sleepless nights." The panel that selected LifeGel to receive the award includes outstanding spine surgeons and neurosurgeons such as: Juan Uribe, MD; Kris Radcliff, MD; Isaac Moss, MDCM, MASc, FRCSC; Stephen Hochschuler, MD; Michael Wang, MD, FACS; and Peter Derman, MD, MBA. "The spine surgical bleeding market is ripe for disruption in this $1.1 billion segment of the $2.8 billion market for surgical hemostat agents," said Jim Buck, Chief Executive Officer at Medcura. "Spine surgery needs a transformational hemostatic technology and LifeGel is the first and only surgical hemostatic agent to receive an FDA Breakthrough Device Designation." Matthew Dowling, PhD invented LifeGel, founded Medcura, and now serves as the company's Chief Scientific Officer and Director. Dr. Dowling bioengineered LifeGel to meet the challenges of hemostasis during spinal surgery. LifeGel — a clear, ready-to-use, fully hydrated, flowable hemostatic gel containing a proprietary combination of hydrophobically modified chitosan, cross-linked gelatin granules, inert copolymers and water — achieves hemostasis mechanically by coating the bleeding site via mucoadhesion. Management of intraoperative bleeding during spinal surgery is critically important to preserve the operative field of view and reduce complications such as transfusions and hematomas, which can lead to increased time, cost, and patient risk. Products currently used for intraoperative bleeding during spinal surgery have been associated with deleterious side effects, and innovations are warranted. Current flowable hemostatic agents routinely used in spinal surgery are known to swell. When used in confined anatomical spaces, they can potentially lead to post-operative neurologic deficits or even paralysis. Medcura's LifeGel mitigates these risks because it achieves hemostasis without swelling. Compared with approved flowable hemostatic agents, LifeGel offers additional benefits, including being highly cost-effective, immediately ready-to-use thereby reducing costly wastage, and complete with antimicrobial properties of its base, chemically inert polymer. "Medcura is on a new wave of true innovation impacting hemostasis in a broad array of areas in medicine," said Dr. Dowling. "I am very proud of the Medcura team, which continues to work towards the advancement of biomaterials science to meaningfully improve how surgeons manage human bleeding in a variety of high-value surgical scenarios." About Medcura Medcura, Inc. is a commercial-stage medical device company developing versatile hemostatic products serving large surgical, medical, and consumer market opportunities. The Company's proprietary technology platform combines the use of safe, inert ingredients with patented chemistries, all aimed at introducing disruptively lower cost products capable of safely and effectively controlling bleeding across a broad spectrum of clinical applications. Medcura has received FDA Breakthrough Device Designations for LifeGel™, which controls surgical bleeding for spine surgeries, and LifeFoam™, a hemostatic agent for traumatic wounds. Learn more about Medcura's growing product line at . Media Contact Shannon Severino [email protected] (412) 608-2393 References LifeGel™ and its application tips are currently in development. All intended uses and/or indications for use for this medical device and its application tips have not been cleared or approved by the FDA. Arista ® AH Absorbable Hemostatic Particles, Instructions for Use,; Warnings. Davol Inc. Subsidiary of C. R. Bard, Inc., Warwick, RI; 2015, Arista-AH Gelfoam ® absorbable gelatin compressed sponge, USP, Instructions for Use; Warnings. Pfizer, Pharmacia & Upjohn Company LLC, New York, NY; 05/2022 Gelfoam ® absorbable gelatin powder from absorbable gelatin sponge, USP, Instructions for Use; Warnings. Pfizer, Pharmacia & Upjohn Company LLC, New York, NY; 05/2022 PerClot ® Polysaccharide Hemostatic System, Instructions for Use, Warnings. Starch Medical Inc., San Jose, CA, Uploaded 2019, PerClot-IFU Surgicel ® Powder, Absorbable Hemostatic Powder, Instructions for Use, Contraindications. Ethicon, LLC, San Lorenzo, Puerto Rico; 05/2017 Surgicel ® SNoW Absorbable Hemostatic, Instructions for Use, Contraindications; Adverse Events. Ethicon, LLC, San Lorenzo, Puerto Rico; 05/2013 SurgifloTM Hemostatic Matrix Kit, Essential Product Information, Warnings; Precautions. Ethicon Johnson and Johnson Surgical Technologies; 2022, SURGIFLO-Hemostatic-Matrix-Brochure SurgicelTM Original/ Surgicel NU-KNIT/ Surgicel Fibrillar Absorbable Hemostats, Instructions for Use, Contraindications; Adverse Events. Ethicon, Neuchâtel, Switzerland; 06/2013 SOURCE Medcura WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

WOONSOCKET, R.I., Jan. 12, 2023 /PRNewswire/ -- CVS Health® (NYSE: CVS) today announced that Sam Khichi will join the company as Executive Vice President, Chief Policy Officer and General Counsel, effective February 13. He will lead the legal, compliance, and government affairs teams who support CVS Health's strategy to make health care more accessible and affordable, leading to better health outcomes for all. "Sam brings diversified experience to many key issues for CVS Health, including geopolitical matters, data privacy, and compliance," said CVS Health President and CEO Karen S. Lynch. "He has an exceptional track record of managing complex health care business and legal strategies." Khichi will become a member of the company's executive leadership team and report to Lynch. Prior to joining CVS Health, he served at Becton Dickinson as Executive Vice President, Corporate Development, Public Policy, Regulatory Affairs and General Counsel. He joined Becton Dickinson through the acquisition of C. R. Bard where he served as Senior Vice President, General Counsel and Secretary, and previously was the Chief Administrative Officer, Senior Vice President and General Counsel at Catalent Pharma Solutions. Khichi has led significant transformations at complex and large-scale health care organizations. "This is an exciting time to join CVS Health and be part of a team whose strategy is redefining how health care is delivered in this country," Khichi said. "I have long admired CVS Health for its innovation and leadership in advancing the consumer health care experience. Achieving transformation of this scale requires changing the way information is shared and technology utilized by consumers, employers, and providers and CVS Health is uniquely positioned to lead this change." Khichi succeeds Tom Moriarty, who plans to retire in April. Moriarty has played a critical role in many significant CVS Health moments, from the company's industry-leading role during the COVID-19 pandemic to helping lead transformative health care acquisitions. About CVS Health CVS Health® is the leading health solutions company, delivering care like no one else can. We reach more people and improve the health of communities across America through our local presence, digital channels and over 300,000 dedicated colleagues – including more than 40,000 physicians, pharmacists, nurses and nurse practitioners. Wherever and whenever people need us, we help them with their health – whether that's managing chronic diseases, staying compliant with their medications or accessing affordable health and wellness services in the most convenient ways. We help people navigate the health care system – and their personal health care – by improving access, lowering costs and being a trusted partner for every meaningful moment of health. And we do it all with heart, each and every day. Follow @CVSHealth on social media. Media contact T.J. Crawford 212-457-0583 [email protected] Investor contact Larry McGrath 800-201-0938 [email protected] SOURCE CVS Health

DUBLIN--( BUSINESS WIRE )--The "Cardiac Catheters & Guidewires Market Size, Share & Trends Analysis Report by Product (Cardiac Catheters, Cardiac Guidewires), by End-use (Hospitals, ASCs), by Region (MEA, APAC, EU), and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering. The global cardiac catheters & guidewires market size is anticipated to reach USD 24.92 billion by 2030, registering a CAGR of 7.56% from 2022 to 2030. The industry is expected to grow due to the increasing geriatric population, lack of substitutes in the market, rising incidence of diabetes across the globe, and technological advancements. Diabetic patients are more prone to develop certain health conditions, such as high cholesterol, high blood pressure, heart diseases, and stroke. In addition, long-term diabetes damages the blood vessels and nerves that directly control the heart muscles. This also increases the chances of developing Cardiovascular Diseases (CVDs). Moreover, people suffering from diabetes also tend to develop heart disease and stroke at a very young age. Furthermore, diabetes triggers the risk of developing obesity, which, in turn, increases the predisposition to CVDs. The high incidence of diabetes is one of the major reasons for the increased prevalence of CVDs across the globe. For instance, according to the American Diabetes Association, around 37.3 million Americans, which was around 11.3% of the total population, were estimated to be suffering from diabetes. Moreover, as per the 10th edition of the International Diabetes Federation, 537 million people worldwide have diabetes, which is anticipated to reach 700 million by 2045. Furthermore, in recent years, the Caribbean, Middle East, Latin America regions, and some nations of the Pacific Islands marked the highest prevalence of diabetes in the world. Moreover, technological advancements in cardiac catheters & guidewires devices can support clinicians in identifying patients with a high risk of disease, which is anticipated to spur the industry growth. For instance, in February 2022, Medtronic received FDA expanded approval for cryoablation cardiac catheters for pediatric patients for the treatment of a common heart rhythm disorder. Hence, such product launches provide growth opportunities. The COVID-19 pandemic had a negative impact on the industry due to a decrease in surgical procedure volumes. However, due to the ease in restrictions, countries have resumed elective procedures, suggesting that the industry will keep growing during the projected period. Cardiac Catheters & Guidewires Market Report Highlights The cardiac catheters segment led the industry in 2021 due to the introduction of technologically advanced products, rising number of coronary interventional procedures, and increasing incidence of diabetes The hospital end-use segment is expected to lead the industry during the forecast years due to the increasing prevalence of chronic diseases, rapidly growing geriatric population, and technological advancements in catheters Asia Pacific is expected to register the fastest CAGR over the forecast period. Growing awareness levels, increasing disposable income, and rising incidence of chronic conditions are the key factors boosting the region's growth The industry is highly competitive due to the presence of many international companies Market Dynamics Drivers Rising Prevalence Of Cardiovascular Diseases (CVDs) Rising Incidence Of Diabetes Across The Globe Favorable Reimbursement Policies For Coronary Intervention Procedures Restraints Minimal Use Of Ivus Catheters In The Developing Countries Lack Of Skilled Professionals In The Low- And Middle-Income Countries Stringent Regulatory Policies Related To The Product Approval Opportunities Development Of Specialized Devices And Treatment Techniques Launch Of New Product Lines In The Market Companies Mentioned Abbott Boston Scientific Corporation Getinge Ab Biosense Webster, Inc (Part of Johnson & Johnson) Microvention (Terumo Corporation) Biotronik Se & Co. Kg Medtronic Cordis (A, Cardinal Health Company) Qxmedical Teleflex Incorporated B. Braun C. R. Bard, Inc Cardinal Health Merit Medical Systems Nipro Brosmed Medical Co. Ltd. For more information about this report visit https://www.researchandmarkets.com/r/csqlc1